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Background: Knowledge of comorbid disorders is important to optimize therapy in multiple 
sclerosis (MS), but data are limited. The aim of this study was to assess comorbidity in 
persons with MS living in Nordland County on January 1, 2017.  
Methods: Data were retrieved from the Norwegian Patient Registry (2008-2017) and 
validated through review of electronic hospital charts (1970-2017). Comorbidity was defined 
as any distinct disorder, classified in the International Classification of Disease (ICD-10), that 
had existed or occurred after the diagnosis of MS was set.  
Results: Data from 637 subjects were reviewed, and 97.5% were registered with at least one 
comorbid condition. Inflammatory bowel disease was confirmed in 1.3%, epilepsy in 2.8%, 
psychosis in 0.6%, hypothyroidism in 3.1%, type-1 diabetes in 0.3%, type-2 diabetes in 3.9%, 
myocardial infarction in 1.7%, cerebral infarction in 0.6%, subarachnoid hemorrhage in 0.2% 
and pulmonary embolism in 0.9%. Fourteen women, 3.3%, had breast cancer. Malignant 
melanoma was found in 0.5%, and non-melanoma skin cancers in 1.9%. 
Conclusion: Compared to reports from other Norwegian epidemiologic studies, a higher 
proportion of inflammatory bowel disease and epilepsy was found. This is in accordance with 
findings from other studies. The prevalence of non-melanoma skin cancers was significantly 







Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), affecting mainly young adults [1]. Without tailored therapy, most patients will 
eventually develop severe disability. Early diagnosis and treatment is thus important in order 
to protect the CNS and maintaining function [2]. In patients with MS, comorbidity increases 
the diagnostic delay [3], and initiation of disease modifying therapy [4]. A complete 
knowledge of comorbidity is important to optimize risk stratification of individual patients for 
personalized therapies [5, 6]. 
One way to assess co-occurring disorders in persons with MS, is to use data from medical 
registers. The Norwegian Patient Registry (NPR) is a nationwide health register run by the 
Norwegian Directorate of Health. It was established in 1997, and the information is 
individually identifiable from 2008. Whenever a patient is treated in a hospital or by a private 
practice specialist with public reimbursement, the given diagnoses with the corresponding 
International Classification of Disease version 10 (ICD-10) codes are mandatorily reported to 
the NPR. By application, researchers may get access to these data. All Norwegian citizens are 
given a unique eleven-digit personal identity number, that is retained throughout life. This 
number is included in every hospital record, and is linked to another unique number in the 
NPR. 
The aim of this study was to assess comorbidities in a cross-sectional population based cohort 






Nordland County covers an area of 38.463 km2 in the northern part of Norway (figure 1). The 
population was 242 866 (119 758 women and 123 108 men) per January 1, 2017. The mean 
age of the inhabitants was 41.7 years. 
The population in Norway was 5 258 317 (2 609 187 women and 2 649 130 men), and the 
mean age was 39.9 years. In total, 3 995 587 inhabitants were 20 years or older [7]. 
In Nordland, only public specialist health care in neurology exists, and includes the 
Department of Neurology at Nordland Hospital in Bodø and the neurological outpatient 
services at the hospitals in Mosjøen and Stokmarknes. 
 
Methods 
On the prevalence date January 1, 2017, 657 persons had confirmed MS in Nordland County 
according to criteria of Poser [8] or McDonald [9, 10]. However, only 637 had the MS 
diagnosis correct registered in the NPR [11], and these are the subjects included in the study. 
From the NPR, we retrieved all additional ICD-10 codes registered from the information that 
became individually identifiable in 2008 up to the prevalence date. For each individual in this 
cohort the medical records were scrutinized, and the comorbid condition was not included if it 
could not be confirmed.  
 
Comorbidity was defined as any distinct condition or disorder that had existed or occurred 
after the diagnosis of MS was set [12].Cancers and chronic diseases were included regardless 
of the start before or after the diagnosis of MS. Acute disorders, however, such as myocardial 






The prevalence of the different comorbid diseases in the MS population was calculated by 
dividing the number of individuals with a disease by the total number of MS patients. The age 
standardized prevalence was calculated by the use of data from a standard European 
population [13]. For the acute occurring vascular comorbidities, the mean annual incidence 
was calculated by divide the number of new cases by person-years. Demographics of the 
population were obtained from Statistics Norway [7]. Cancer frequencies in Norway as of 
December 31, 2016, were obtained from the Cancer Registry of Norway [14]. The prevalence 
of cancer in the Nordland County MS population was compared to the calculated prevalence 
in the Norwegian population using chi-square tables. The significance level was set to p < 
0.05. 
Statistical analyses were performed by the use of Microsoft Excel for Windows 7 and IBM 
SPSS Statistics version 25. 
 
Results 
On January 1, 2017, 637 individuals in Nordland County were correctly registered with MS in 
the NPR [11], 426 women, mean age 52.5 (±13.5) years, and 211 men, mean age 52.1 (±14.2) 
years. Three hundred and fifty-nine individuals were diagnosed with MS before 2008 and 278 
after. The total person-years living with MS in Nordland in the period 2008 - 2017 was 4392. 
One or more comorbid conditions were registered in the NPR in 621 (97.5%) of the patients. 






Cancer was registered in the NPR for 45 MS patients. Of those 41 were registered correctly 
according to the hospital records (table 2). The mean age at the prevalence point was 62.2 
(±10.0) years. The prevalence of overall cancer was 6.4%. 
Malignant melanoma (C43) was correctly registered in three of the MS patients. The mean 
age at prevalence point was 50.7 (±5.3) years. The prevalence of malignant melanoma was 
0.5%. 
Non-melanoma skin cancer (C44) was correctly registered in 11 patients. The mean age at 
prevalence point was 63.1 (±10.2) years, ranging from 40 to 73 years. The age at the MS 
diagnosis was 44.3 (±12.1) years and the age of cancer was 57.7 (±10.3) years. Nine 
individuals got the diagnosis of MS before they got the non-melanoma skin cancer, of whom 
four had used disease modifying therapy (table 3). The prevalence of non-melanoma skin 
cancer was 1.7%. This is significantly higher than in the Norwegian population, according to 
The Cancer registry of Norway, where the prevalence is 0.29%, p < 0.001. In the population 
aged 20 years and above, the prevalence is 0.38%, and the difference remained significant, p 
< 0.001.  
Breast cancer (C50) was correctly registered in the NPR for 14 women. The mean age at 
prevalence point was 61.1 (±13.7) years. The prevalence of breast cancer was 3.3% in women 
with MS. This was significantly higher than in the Norwegian female population, where the 
prevalence is 1.74%, p = 0.015. However, when compared to the prevalence of the Norwegian 
female population aged 20 years and above, where the prevalence is 2.28%, the difference 
was non-significant, p = 0.16. 
One MS patient was registered with colon cancer (C18), and none was registered with cancer 






An overview of the non-malign comorbid disorders is given in table 4. 
 
Thyroid disorder was registered in the NPR for 26 MS patients. One was registered with 
“Post-procedural endocrine and metabolic disorders, not elsewhere classified” (E89), but in 
the hospital record no indication of thyroid disorder was found. Twenty were registered with 
“Other hypothyroidism” (E03), and the diagnosis was confirmed in 19, of which four had 
elevated anti-thyroid peroxidase (TPO) and one had elevated anti- thyroglobulin. Four were 
registered with “Other nontoxic goiter” (E04), but only three actually had goiter. One of these 
had elevated TPO, and in total six individuals had elevated antibody levels. One was 
registered with “Thyrotoxicosis” (E05), but actually suffered from hypothyroidism. Hence, 20 
(3.1%) MS patients, 16 (3.8%) women and 4 (1.9%) men, had hypothyroidism, four with 
increased TPO and one with increases anti-thyroglobulin. Twelve were diagnosed with 
hypothyroidism after the MS diagnosis, two in the wake of alemtuzumab treatment. The 
prevalence of thyroid disorder was 3.6%. 
 
Diabetes mellitus (DM) was registered in the NPR for 29 MS patients. Twenty-six were 
registered with type-2 DM (E11), but the diagnosis was incorrect for two patients. Of the 
three patients registered with type-1 DM (E10), one had insulin treated type-2 DM. The 
prevalence of type-1 DM was 0.3%, and of type-2 DM 3.9%  
 
Psychosis was registered in the NPR for four MS patients, one in each of the diagnostic group 
“unspecified organic or symptomatic mental disorder” (F09), schizophrenia (F20), “acute and 
transient psychotic disorders” (F23) and schizoaffective disorders (F25). We confirmed that 




time of the first registered psychotic episode. The mean age at the prevalence point was 46.3 
(±15.1) years. The mean age at the time of the MS diagnosis was 38.8 (±17.8) years and the 
mean age at the time of the psychosis diagnosis 36.3 (±21.4) years. The prevalence of 
psychosis was 0.6%. 
 
Epilepsy (G40) was registered in the NPR for 20 MS patients, but the diagnosis was incorrect 
for two of them. The mean age at the prevalence point was 24.4 (±13.8) years. The mean age 
at the time of the MS diagnosis was 38.9 (±11.5) years and the mean age at the time of the 
epilepsy diagnosis 41.1 (±16.1) years. The prevalence of epilepsy was 2.8%.  
 
Acute myocardial infarction (I21) was registered in the NPR for 11 MS patients, four women 
and seven men. All were registered correctly, and all had MS at the time of the myocardial 
infarction. The mean annual incidence was 250.4 per 100 000. The mean age at prevalence 
point was 65.8 (±9.9) years. The mean age at the time of the infarction was 61.4 (±9.0) years, 
and the mean duration for MS was then 16.1 (±10.0) years. The prevalence of myocardial 
infarction was 1.7% 
 
Pulmonary embolism (I26) was registered in the NPR for six MS patients, five women and 
one man. The diagnosis was confirmed in everyone, and all had the MS diagnosis at the time 
of the embolism. The mean annual incidence was 136.6 per 100 000. The mean age at the 
event was 51.0 (±8.7) years, and the mean duration for MS was then13.3 (±8.7) years. The 





Subarachnoid hemorrhage (I60) was correctly registered in the NPR for one MS patient.. The 
prevalence of subarachnoid hemorrhage was 0.2%. Intracerebral hemorrhage (I61) was not 
registered in NPR in any MS patients.  
 
Cerebral infarction (I63) was registered in the NPR for 12 MS patients. One, however, had 
suffered the stroke prior to 2008. Of the remaining, only four had a correct diagnosis, giving a 
mean annual incidence of 91.7 per 100 000. The mean age at prevalence point was 63.0 
(±12.0) years. The mean age at the time of the stroke was 58.8 (±13.1) years, and the mean 
duration for MS was then 16.5 (±10.3) years. The prevalence of cerebral infarction was 0.6%. 
 
Inflammatory bowel disease (IBD) was registered in the NPR for ten MS patients. One, 
however, had a gastric ulcer and another had a colon polyp. Hence, eight MS patients had 
IBD, four with Crohn’s disease (K50) and four with ulcerative colitis (K51). Six individuals 
(75%) were diagnosed with IBD before they were diagnosed with MS. The mean age at 
prevalence point was 52.9 (±13.4) years. The mean age at the diagnosis of MS was 41.9 
(±10.2) and the mean age at the diagnosis of IBD was 37.3 (±15.7) years. The prevalence of 
IBD was 1.3%. 
 
Rheumatoid arthritis (RA) was registered in the NPR for nine MS patients, but the diagnosis 
was incorrect for four. Two patients had seropositive RA (M05) and two had seronegative RA 
(M06). None were registered with juvenile arthritis (M08). All were diagnosed with MS 
before they were diagnosed with RA. The mean age at prevalence point was 61.3 (±11.5) 




diagnosis of RA was 54.3 (±16.6) years. The prevalence of RA was 0.6%.  
SLE was registered in the NPR for one patient, but the diagnosis was incorrect. 
 
Discussion 
In the present study 97.5% of the persons with MS were registered with comorbid conditions 
in the NPR, and comorbidity is thus prevalent in a cross-sectional MS-population. 
 
Due to the large number of different comorbidities registered, a discretionary selection of 
conditions was validated. This was based on findings in the screening process, information 
from existing literature, and the likelihood of the disorder being treated and registered in 
hospitals or by a specialist. 
 
The mean age of our MS cohort was 52.5 years, compared to 39.9 years in the general 
Norwegian population. This limits the possibility to compare our results directly with data 
from the general population. To account for this, we therefore compared some of our figures 
with data from the adult population, 20 years of age and above. This was found relevant for 
non-melanoma skin cancer and breast cancer. The incidence of these types of cancer is rare in 
individuals younger than 20 years [14, page 32-35]. 
 
Low exposure of sun during childhood seems to be a risk factor for MS in our area [15]. 
Nordland County is located in high latitude with limited sun exposure during the year. Studies 
have found an association to latitude and low sun exposure, vitamin D and melanoma and 
non-melanoma skin cancer rates [16]. Based on this, low occurrence of melanoma and non-




incidence of skin cancer in the MS group [17]. In a more recent Canadian study, however, the 
risk of non-melanoma skin cancer was significantly increased in patients with relapsing-onset 
MS [18]. Data regarding malignant melanoma are contradictive, and increased incidence of 
malignant melanoma has also been reported [19]. We found a prevalence of malignant 
melanoma of 0.5% in the MS population, which is equal to the general Norwegian population. 
[14]. The prevalence of non-melanoma skin cancer, however, was significantly higher than 
what is found in the general population. 
 
Some studies indicate increased incidence of breast cancer in the MS population [20]. We 
found a higher prevalence when compared with the prevalence in the total Norwegian 
population. However, when using data from the population 20 years and older the difference 
was no longer significant, and the increased incidence found is probably explained by the age 
in the MS-cohort. 
 
Smoking is considered a risk factor for MS [21], and is a major cause of lung- and urinary 
bladder cancer. We have recently reported increased risk of cancers in the respiratory organs, 
from a large MS-cohort [22], but this was not confirmed in this cohort from Nordland County. 
The same study also reported increased risk of cancers in the urinary tract organs that was not 
confirmed in this cohort. The longitudinal (life-long for several patients) study design, 
compared to this cross-sectional cohort study, may explain this difference. Unfortunately, we 
did not have reliable data on smoking from our MS population. 
 
In the present study the prevalence of IBD was 1.3%, that was 1.6 times higher than reported 
in a general Norwegian population, where the prevalence was 262 per 100 000 for Crohn’s 




with other international studies. An increased risk of IBD in MS patients, as well as an 
increased risk of MS in IBD patients has previously been shown [24]. 
We found hypothyroidism in 3.7% of the women and 1.8% of the men in the MS population. 
This is lower than the findings from a previous Norwegian study in a general population [25]. 
Increased risk of thyroid disease among MS patients has been reported [26], but contradicted 
by others [27]. We also found a low prevalence of DM compared to a recent Norwegian 
study, where the prevalence of type 2 diabetes mellitus was 6.1% [28]. Both hypothyroidism 
and type 2 diabetes are most often diagnosed and treated by general practitioners, and thus not 
necessarily registered in the NPR, probably giving underestimated prevalence figures in our 
cohort.   
We found rheumatoid arthritis  in 0.6% in the MS population, that was comparable to figures 
reported from the neighboring county , where the prevalence was 0.47% in 1994 [29]. 
 
We confirmed that epilepsy is frequent in MS, with prevalence four times more frequent than 
in the general Norwegian population of 0.7% [30]. The increased prevalence of epilepsy is in 
accordance with other studies [31].  
A Norwegian study from 2001 found a lifetime prevalence of non-affective psychosis of 0.4% 
in the general population [32]. We found the prevalence of individuals who have experienced 
psychosis to be slightly larger, 0.6%, but the numbers afflicted are too small to a make a 
reliable statistic interpretation. Others have found an increased prevalence of psychosis in the 
MS population [33]. 
 
A recent study reported an increased risk of acute myocardial infarction in MS patients [34]. 
In the Nordland MS population, the mean annual incidence of myocardial infarction was 




years, the age and sex adjusted incidence of myocardial infarction in 2010  was 224 per 
100 000 [35]. Studies have also found increased incidence of stroke among MS patients [36]. 
In the present study, 1.7% of the MS-population had suffered stroke in the period, with a 
mean annual incidence of 91.7 per 100 000. In comparison, a study from Northern Norway of 
individuals in the normal population older than 30 years found 367 strokes per 116 703 
person-years in the period 2006 – 2010, giving an annual incidence of 314.5 per 100 000 [37].  
We found that only four out of 11 registered with cerebral infarction (I63) in the NPR actually 
had suffered from stroke. For the others, the symptoms and findings were considered as 
manifestations of their MS. In a clinical setting, it is sometimes difficult to distinguish stroke 
from exacerbation of MS. Regarding classification and epidemiology, such difficulties may 
cause diagnostic misinterpretation in both directions. 
 
Our data was validated and compared to reliable national data from the Cancer Registry of 
Norway and relevant epidemiologic studies. However, we did not have a matched validated 
control groups, and only diagnosis registered in the NPR were included. Important conditions, 
such as depression, anxiety and psoriasis, as well as risk factors like hypertension and 
hyperlipidemia, are presumed to be handled mostly in primary care, and have thus been 
omitted, since these are therefore not registered into the NPR. Furthermore, we cannot 
exclude that other conditions also are under-reported to the NPR, and in that respect our 
figures may represent the lower limit of the real occurrence of comorbidities in MS.      
 
Conclusion 
The present study confirms an increased prevalence of inflammatory bowel disease and 
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Table 1. Individuals with diagnosis according to ICD10 as registered in the NPR 
 
Chapter Code range Description Patients 
1 A00-A 
B-B99 











3 D50-D89 Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
32 
4 E00-E89 Endocrine, nutritional and metabolic diseases 134 
5 F01-F99 Mental, Behavioral and Neurodevelopmental disorders 137 
6 G00-G99* Diseases of the nervous system 214 
7 H00-H59 Diseases of the eye and adnexa 288 
8 H60-H95 Diseases of the ear and mastoid process 88 
9 I00-I99 Diseases of the circulatory system 171 
10 J00-J99 Diseases of the respiratory system 139 
11 K00-K95 Diseases of the digestive system 224 
12 L00-L99 Diseases of the skin and subcutaneous tissue 148 
13 M00-M99 Diseases of the musculoskeletal system and connective 
tissue 
263 
14 N00-N99 Diseases of the genitourinary system 368 
 
* Except G35 and G37. ICD10 = International Classification of Disease version 10, NPR = 





Table 2. Cancer in the Nordland MS cohort and in the general Norwegian population  
Cancer in the Nordland County 
MS-population 
Cancer in the 
Norwegian Population 





C00-96 All sites 41 6.44 3.23 262 884 5.00 










1 001 0.02 










1 272 0.02 






C16 Stomach 1 0.16 0.06 1 987 0.04 




1 153 0.02 
C18 Colon 1 0.16 0.08 21 532 0.41 















C23-24 Gallbladder, bile ducts 
 





1 021 0.02 





C30-34, C38 Respiratory organs 0 0 
 
8 979 0.17 









1 108 0.02 















C43 Melanoma of the skin 3 0.47 0.26 24 594 0.47 











C48-49 Soft tissues 0 0 
 
1 599 0.03 
C50 Breast* 14 3.29 1.50 45 492 1.74 
C51-58 Female genital organs* 2 0.47 0.28 22 991 0.88 









7 173 0.27 
C54 Corpus uteri 1 0.23 0.11 10 347 0.40 
C55 Uterus, other 1 0.23 0.17 50 0.00 










C60-63 Male genital organs** 5 2.37 1.17 54 914 2.07 
C61 Prostate 3 1.42 0.58 47 088 1.78 
C62 Testis 2 0.95 0.59 7 483 0.28 





C64-68 Urinary organs 1 0.16 0.09 20 531 0.39 
C64 Kidney (excl. renal pelvis) 1 0,16 0.09 6 816 0.13 









1 086 0.02 




13 165 0.25 




5 718 0.11 




3 900 0.07 
C39, C76, C80 Other or unspecified 1 0.16 0.09 598 0.01 
C81-96 Lymphoid/haematopoietic tissue 1 0.16 0.07 23 378 0.44 




2 799 0.05 




9 672 0.18 
C88 Immunoproliferative disease 1 0.16 0.07 597 0.01 









8 461 0.16 
†based on numbers from Cancer Norway, †† based on numbers from Cancer Norway and 





Table 3. Non-melanoma skin cancer (ICD-10 C44) 
 








Type of skin cancer MS treatment prior 
to skin cancer 
Occupation Ever-
smoker 
1 f 40 39 36 rr basal cell carcinoma none teacher yes 
2 m 57 47 56 rr squamous cell 
carcinoma 
glatiramer acetate office worker yes 










factory worker yes 
5 f 59 48 52 rr basal cell carcinoma interferon beta-1a, 
glatiramer acetate 
secretary no 
6 f 62 29 57 rr basal cell carcinoma none nurse yes 
7 f 70 39 61 ? basal cell carcinoma none shop-keeper yes 
8 m 72 70 68 pp basal cell carcinoma none plumber/clerk yes 
9 m 72 53 60 rr basal cell carcinoma none fisherman/farmer yes 
10 m 73 39 72 rr squamous cell 
carcinoma 
none auto mechanic yes 







Table 4. Non-cancer comorbid conditions in the Nordland County MS cohort 
 
  




Mean age (years) 
at prevalence 
(±SD) 
Hypothyroidism E03 20 3.1 2.0 59.1 (±16.6) 
Diabetes mellitus I E10 2 0.3 0.2 47.0 (±7.1) 
Diabetes mellitus II E11 25 3.9 2.2 62.5 (±12.1) 
Psychosis F09, F20, F23, F25 4 0.6 0.5 46.3 (±15.1) 
Epilepsy G40 18 2.8 1.8 54.4 (±13.8) 
Myocardial infarction I21 11 1.7 0.8 65.8 (±9.9) 
Pulmonary embolism I26 6 0.9 0.5 56.0 (±8.2) 
Stroke intracerebral hemorrhage I61 0 0 0 - 
Stroke subarachnoid hemorrhage I62 1 0.2 0.1 74 
Stroke infarction I63 4 0.6 0.3 63.0 (±12.0) 
Inflammatory bowel disease K50, K51 8 1.3 0.8 52.9 (±13.4) 
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